WO2007028633A3 - Treatment of diabetes related obesity - Google Patents

Treatment of diabetes related obesity Download PDF

Info

Publication number
WO2007028633A3
WO2007028633A3 PCT/EP2006/008780 EP2006008780W WO2007028633A3 WO 2007028633 A3 WO2007028633 A3 WO 2007028633A3 EP 2006008780 W EP2006008780 W EP 2006008780W WO 2007028633 A3 WO2007028633 A3 WO 2007028633A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
diabetes related
related obesity
treating
gip
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/008780
Other languages
French (fr)
Other versions
WO2007028633A2 (en
Inventor
Finbarr Paul Mary O'harte
Peter Raymond Flatt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UUTech Ltd
Original Assignee
UUTech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UUTech Ltd filed Critical UUTech Ltd
Priority to EP06805676A priority Critical patent/EP1943274A2/en
Priority to US11/991,639 priority patent/US20090170762A1/en
Priority to CA002622069A priority patent/CA2622069A1/en
Publication of WO2007028633A2 publication Critical patent/WO2007028633A2/en
Publication of WO2007028633A3 publication Critical patent/WO2007028633A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Peptide analogues and uses are provided for treating and preventing obesity and for treating, preventing and reversing weight gain and related metabolic disease, and promoting weight loss and weight maintenance, by administering a medicament comprising an antagonist of GIP receptor, which is a peptide analogue of GIP.
PCT/EP2006/008780 2005-09-08 2006-09-08 Treatment of diabetes related obesity Ceased WO2007028633A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP06805676A EP1943274A2 (en) 2005-09-08 2006-09-08 Treatment of diabetes related obesity
US11/991,639 US20090170762A1 (en) 2005-09-08 2006-09-08 Treatment of Diabetes Related Obesity
CA002622069A CA2622069A1 (en) 2005-09-08 2006-09-08 Treatment of diabetes related obesity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71533605P 2005-09-08 2005-09-08
US60/715,336 2005-09-08

Publications (2)

Publication Number Publication Date
WO2007028633A2 WO2007028633A2 (en) 2007-03-15
WO2007028633A3 true WO2007028633A3 (en) 2007-06-07

Family

ID=37836187

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/008780 Ceased WO2007028633A2 (en) 2005-09-08 2006-09-08 Treatment of diabetes related obesity

Country Status (4)

Country Link
US (1) US20090170762A1 (en)
EP (1) EP1943274A2 (en)
CA (1) CA2622069A1 (en)
WO (1) WO2007028633A2 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859491B2 (en) 2011-11-17 2014-10-14 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
US8900593B2 (en) 2007-02-15 2014-12-02 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US8969288B2 (en) 2008-12-19 2015-03-03 Indiana University Research And Technology Corporation Amide based glucagon and superfamily peptide prodrugs
US8980830B2 (en) 2007-10-30 2015-03-17 Indiana University Research And Technology Corporation Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity
US9018164B2 (en) 2005-11-07 2015-04-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
US9127088B2 (en) 2010-05-13 2015-09-08 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
US9145451B2 (en) 2010-05-13 2015-09-29 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhbiting G protein coupled receptor activity
US9150632B2 (en) 2009-06-16 2015-10-06 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
US9156902B2 (en) 2011-06-22 2015-10-13 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US9249206B2 (en) 2010-12-22 2016-02-02 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
US9309301B2 (en) 2011-06-22 2016-04-12 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US9340600B2 (en) 2012-06-21 2016-05-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
US9487571B2 (en) 2010-01-27 2016-11-08 Indiana University Research And Technology Corporation Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272652A1 (en) * 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
US20090286722A1 (en) * 2005-09-08 2009-11-19 Utech Limited Analogs of Gastric Inhibitory Polypeptide as a Treatment for Age Related Decreased Pancreatic Beta Cell Function
WO2009058662A2 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Glucagon antagonists
WO2009155257A1 (en) 2008-06-17 2009-12-23 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers
DK2300035T3 (en) 2008-06-17 2015-11-16 Univ Indiana Res & Tech Corp Mixed GIP-based agonists for the treatment of metabolic diseases and obesity
AU2009280021B2 (en) * 2008-08-07 2012-10-04 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide (GIP) modified at N-terminal
JP2011530507A (en) 2008-08-07 2011-12-22 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ Glucose-dependent insulinotropic polypeptide analog
KR101417873B1 (en) * 2008-08-07 2014-07-09 입센 파마 에스.에이.에스 Analogues of glucose-dependent insulinotropic polypeptide
US9724381B2 (en) * 2009-05-12 2017-08-08 The Administrators Of The Tulane Educational Fund Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US9023986B2 (en) 2010-10-25 2015-05-05 Hoffmann-La Roche Inc. Glucose-dependent insulinotropic peptide analogs
US20140377171A1 (en) * 2011-06-10 2014-12-25 Jean Claude Reubi Imaging and Treatment of Neuroendocrine Tumors with Glucose - Dependent Insulinotropic Polypeptide or Analogues or Antagonists Thereof
KR102844773B1 (en) 2015-12-23 2025-08-13 암젠 인크 Method for treating or improving metabolic disorders by using a binding protein for the gastric inhibitory peptide receptor (GIPR) in combination with a GLP-1 agonist
BR112019014588A2 (en) * 2017-01-17 2020-02-18 Amgen Inc. METHOD OF TREATING OR AMENIZING METABOLIC DISORDERS USING GLP-1 RECEPTOR AGONISTS CONJUGATED TO ANTAGONISTS FOR GASTRIC INHIBITOR PEPTIDE RECEPTOR (GIPR)
JOP20190211A1 (en) 2017-03-31 2019-09-15 Takeda Pharmaceuticals Co Gip receptor activating peptide
CN110831969B (en) * 2017-06-20 2024-06-21 安进公司 Method for treating or improving metabolic disorders using a combination of gastric inhibitory peptide receptor (GIPR) binding protein and GLP-1 agonist
MX2019015544A (en) 2017-06-21 2020-07-28 Amgen Inc Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (gipr)/glp-1 receptor agonist fusion proteins.
KR102171141B1 (en) * 2018-05-28 2020-10-28 중앙대학교 산학협력단 Composition for preventing, treating, or improving obesity comprising the peptides derived from LGI3 as the active ingredients
WO2021156181A1 (en) * 2020-02-03 2021-08-12 Société des Produits Nestlé S.A. Compositions and methods for the improvement and maintenance of glucose metabolism in childhood and adolescence
WO2025186255A1 (en) * 2024-03-06 2025-09-12 Orion Biotechnology Holding Sa Gipr inhibitors and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005082928A2 (en) * 2004-02-25 2005-09-09 University Of Ulster Peptide analogues of gip for treatment of diabetes, insulin resistance and obesity

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989009393A1 (en) * 1988-03-24 1989-10-05 Igen, Inc. Luminescent chimeric proteins
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
AU672790B2 (en) * 1992-07-15 1996-10-17 Novartis Ag Variants of parathyroid hormone and its fragments
US6077822A (en) * 1993-09-14 2000-06-20 Dumex-Alpharma A/S Drug salts
US6852690B1 (en) * 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
DE19616486C5 (en) * 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Method for lowering the blood glucose level in mammals
US7091183B1 (en) * 1996-12-03 2006-08-15 Boston Medical Center Corporation Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP)
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US5846937A (en) * 1997-03-03 1998-12-08 1149336 Ontario Inc. Method of using exendin and GLP-1 to affect the central nervous system
US5998204A (en) * 1997-03-14 1999-12-07 The Regents Of The University Of California Fluorescent protein sensors for detection of analytes
JP2002526554A (en) * 1998-10-07 2002-08-20 メディカル カレッジ オブ ジョージア リサーチ インスティチュート，インコーポレイテッド Glucose-dependent insulin-affinity peptide used as bone-affinity hormone
US7745216B2 (en) * 1999-02-10 2010-06-29 Curis, Inc. Methods and reagents for treating glucose metabolic disorders
US20050272652A1 (en) * 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
PT1171465E (en) * 1999-03-29 2004-12-31 Uutech Ltd ANALYSIS OF A GASTRIC INHIBITOR AND THEIR USE FOR THE TREATMENT OF DIABETES
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6849714B1 (en) * 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6245320B1 (en) * 1999-09-01 2001-06-12 University Of Maryland Inhibition of mucin release from airway goblet cells by polycationic peptides
WO2001087341A1 (en) * 2000-05-16 2001-11-22 Sanwa Kagaku Kenkyusho Co.,Ltd. Agents for preventing or ameliorating insulin resistance and/or obesity
WO2002010195A2 (en) * 2000-08-02 2002-02-07 Theratechnologies Inc. Modified peptides with increased potency
EP1411968B1 (en) * 2001-07-31 2008-09-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Glp-1 exendin-4 peptide analogs and uses thereof
US7176278B2 (en) * 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US20030232761A1 (en) * 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
AU2003248676A1 (en) * 2002-06-15 2003-12-31 Enteromed, Inc. Treatment of non-alcoholic fatty liver disease
AU2004240630B2 (en) * 2003-05-15 2010-10-07 Trustees Of Tufts College Stable analogs of peptide and polypeptide therapeutics
US20090286722A1 (en) * 2005-09-08 2009-11-19 Utech Limited Analogs of Gastric Inhibitory Polypeptide as a Treatment for Age Related Decreased Pancreatic Beta Cell Function

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005082928A2 (en) * 2004-02-25 2005-09-09 University Of Ulster Peptide analogues of gip for treatment of diabetes, insulin resistance and obesity

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GAULT V A ET AL: "Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential?", NEUROPEPTIDES, XX, XX, vol. 37, 2003, pages 253 - 263, XP002348873, ISSN: 0143-4179 *
GAULT VICTOR A ET AL: "Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro(3))GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes", DIABETES, vol. 54, no. 8, August 2005 (2005-08-01), pages 2436 - 2446, XP002428432, ISSN: 0012-1797 *
HINKE SIMON A ET AL: "In depth analysis of the N-terminal bioactive domain of gastric inhibitory polypeptide", LIFE SCIENCES, PERGAMON PRESS, OXFORD, GB, vol. 75, no. 15, 27 August 2004 (2004-08-27), pages 1857 - 1870, XP002387302, ISSN: 0024-3205 *
IRWIN N ET AL: "A NOVEL, LONG-ACTING AGONIST OF GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE SUITABLE FOR ONCE-DAILY ADMINISTRATION IN TYPE 2 DIABETES", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND, US, vol. 314, no. 3, September 2005 (2005-09-01), publicly available on-line on 27.05.2005, pages 1187 - 1194, XP008052103, ISSN: 0022-3565 *
IRWIN NIGEL ET AL: "Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL(16)) and N-AcGIP(LysPAL(37))", BIOLOGICAL CHEMISTRY, vol. 386, no. 7, July 2005 (2005-07-01), pages 679 - 687, XP002428433, ISSN: 1431-6730 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9018164B2 (en) 2005-11-07 2015-04-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
US8900593B2 (en) 2007-02-15 2014-12-02 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US9447162B2 (en) 2007-02-15 2016-09-20 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US8980830B2 (en) 2007-10-30 2015-03-17 Indiana University Research And Technology Corporation Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity
US8969288B2 (en) 2008-12-19 2015-03-03 Indiana University Research And Technology Corporation Amide based glucagon and superfamily peptide prodrugs
US9150632B2 (en) 2009-06-16 2015-10-06 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
US9487571B2 (en) 2010-01-27 2016-11-08 Indiana University Research And Technology Corporation Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity
US9145451B2 (en) 2010-05-13 2015-09-29 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhbiting G protein coupled receptor activity
US9127088B2 (en) 2010-05-13 2015-09-08 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
US9249206B2 (en) 2010-12-22 2016-02-02 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
US9156902B2 (en) 2011-06-22 2015-10-13 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US9309301B2 (en) 2011-06-22 2016-04-12 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US8859491B2 (en) 2011-11-17 2014-10-14 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
US9340600B2 (en) 2012-06-21 2016-05-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity

Also Published As

Publication number Publication date
EP1943274A2 (en) 2008-07-16
WO2007028633A2 (en) 2007-03-15
CA2622069A1 (en) 2007-03-15
US20090170762A1 (en) 2009-07-02

Similar Documents

Publication Publication Date Title
WO2007028633A3 (en) Treatment of diabetes related obesity
WO2007087468A3 (en) Adiponectin for treatment of various disorders
PH12022550232A1 (en) Gipr-agonist compounds.
NZ593813A (en) Glucagon analogues
DK2158214T3 (en) Glucagon analogues
IL219915A0 (en) Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
WO2008055940A3 (en) Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions
EP2799447A3 (en) Glucagon analogues
WO2007104789A3 (en) Amylin derivatives
WO2005082928A3 (en) Peptide analogues of gip for treatment of diabetes, insulin resistance and obesity
WO2006024275A3 (en) Glp-1 and exendin related invention
WO2007124461A3 (en) Glp-1 compounds
EP2322620A3 (en) Analogs of human pancreatic polypeptide and their effects on feeding behaviour
WO2007060140A3 (en) Inhibitors of diacyglycerol acyltransferase (dgat)
WO2007009894A3 (en) Peptides for use in the treatment of obesity
WO2006044775A3 (en) Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
MX2012006744A (en) Ppar-sparing thiazolidinediones and combinations for the treatment of diabetes mellitus and other metabolic diseases.
WO2005044192A3 (en) Triazole compounds and uses related thereto
WO2007105113A3 (en) Use of crf1 receptor antagonists for preparing a drug for treating metabolic syndrome and/or obesity and/or dyslipoproteinemia
DE602006009095D1 (en) Diacylglycerol-acyltransferase-hemmer
MY181731A (en) Azole benzene derivative
WO2009041663A1 (en) Agent for prevention and/or treatment of skin diseases
UA100527C2 (en) Benzothiazoles as ghrelin receptor modulators
WO2008105507A1 (en) Therapeutic agent for spinal cord injury
WO2008103378A3 (en) Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2622069

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006805676

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06805676

Country of ref document: EP

Kind code of ref document: A2

WWP Wipo information: published in national office

Ref document number: 2006805676

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11991639

Country of ref document: US